Latest news
25 items- PRBeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung CancerPositive opinion for first-line treatment of extensive-stage small cell lung cancer based on results of RATIONALE-312 study demonstrating statistically significant overall survival benefit for TEVIMBRA in combination with chemotherapy BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell lu
- PRTEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with ChemotherapyNew indication based on results from a global Phase 3 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival for patients with advanced gastric cancers Second FDA approval for TEVIMBRA in 2024 BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors e
- SECBeiGene Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BeiGene, Ltd. (0001651308) (Filer)
- PRBeiGene to Change Nasdaq Ticker Symbol to "ONC" on January 2; Present at 43rd Annual J.P. Morgan Healthcare ConferenceBeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., announced it will change its Nasdaq ticker symbol to "ONC" on January 2, 2025, reflecting its long-standing commitment to delivering innovative oncology medicines globally. "As we enter our 15th year, changing our ticker to ONC reflects our unwavering commitment to leadership in oncology and mission to deliver transformative medicines to cancer patients worldwide," said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. "This milestone inspires pride in all we have accomplished and fuels our excitement for the future as we advance our innovative h
- INSIDERChief Executive Officer Oyler John exercised 1,300,000 units of Ordinary Shares at a strike of $0.50, increasing direct ownership by 77% to 2,978,833 units (SEC Form 4)4 - BeiGene, Ltd. (0001651308) (Issuer)
- PRBeiGene Announces Global Licensing Agreement for MAT2A InhibitorBeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. ("CSPC") for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. SYH2039 targets solid tumors that have a mutation called MTAP deletion, which is estimated to be present in approximately 15 percent of all cancer types with the most common including glioblastoma, pancreatic cancer and non-small cell lung cancer. "With one of the most dynamic solid tumor portfolios in the
- INSIDERChair, Scientific Advisory Brd Wang Xiaodong sold $7,805,106 worth of American Depositary Shares (41,760 units at $186.90) and exercised 41,760 units of American Depositary Shares at a strike of $6.50 (SEC Form 4)4 - BeiGene, Ltd. (0001651308) (Issuer)
- 13D/GAmendment: SEC Form SC 13D/A filed by BeiGene Ltd.SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)
- INSIDERDirector Baker Bros. Advisors Lp sold $194,200,043 worth of American Depositary Shares (1,037,017 units at $187.27) (SEC Form 4)4 - BeiGene, Ltd. (0001651308) (Issuer)
- INSIDERPresident, COO & GM China Wu Xiaobin sold 0 units of RMB Shares (SEC Form 4)4 - BeiGene, Ltd. (0001651308) (Issuer)
- SECBeiGene Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - BeiGene, Ltd. (0001651308) (Filer)
- SECSEC Form 144 filed by BeiGene Ltd.144 - BeiGene, Ltd. (0001651308) (Subject)
- SECSEC Form 144 filed by BeiGene Ltd.144 - BeiGene, Ltd. (0001651308) (Subject)
- PRBeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL, further solidifying its position as the leader in new patient starts in both frontline and relapsed/refractory (R/R) CLL with the broadest label of any BTK inhibitor At a median follow-up of 1.5 years, promising data from the 320 mg expansion cohort of phase 1/1b study shows no progression in patients with treatment-naïve CLL treated with sonrotoclax, a next-generation BCL2 inhibitor, in combination with BRUKINSA highlighting the potential of this fixed-duration, oral-only combination as a best-in-
- INSIDERLarge owner Hhlr Advisors, Ltd. sold $3,568,500,000 worth of Ordinary Shares (17,842,500 units at $200.00) (SEC Form 4)4 - BeiGene, Ltd. (0001651308) (Issuer)
- 13D/GAmendment: SEC Form SC 13D/A filed by BeiGene Ltd.SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)
- PRBeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLLAbout 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely to be efficacious Campaign highlights national treatment guidelines supporting targeted therapies rather than chemotherapy for improved CLL outcomes BeiGene and CLL Society launch partnership during the American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 7-10 in San Diego, California BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced its new partner
- ANALYSTMorgan Stanley resumed coverage on BeiGene with a new price targetMorgan Stanley resumed coverage of BeiGene with a rating of Overweight and set a new price target of $300.00
- PRBeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it will host an investor webcast on December 16, 2024 at 8:30 am EST. The Company's R&D leadership team will provide an update on BeiGene's innovative portfolio and pipeline, focusing on key presentations at the American Society of Hematology Meeting (ASH) and the San Antonio Breast Cancer Symposium. The live webcast of this event can be accessed from the investors section of BeiGene's website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. An archived replay will be available for 90 days following th
- INSIDERChair, Scientific Advisory Brd Wang Xiaodong exercised 38,461 units of American Depositary Shares at a strike of $6.50 and sold $9,190,570 worth of American Depositary Shares (48,351 units at $190.08), closing all direct ownership in the company (SEC Form 4)4 - BeiGene, Ltd. (0001651308) (Issuer)
- PREuropean Commission Approves BeiGene's TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction CancerNew indications based on two Phase 3 studies demonstrating statistically significant overall survival benefit for patients treated with TEVIMBRA in combination with chemotherapy BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines, today announced that the European Commission has approved TEVIMBRA® (tislelizumab) in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. "Patients diagnosed with advanced gastric and esophageal cancers confront median survival times measured in months, not years—hi
- PRBeiGene to Present at Upcoming Investor ConferencesBeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it will participate in fireside chats at two upcoming investor conferences: Citizens JMP Hematology and Oncology Summit on Monday, December 2 at 1:00 p.m. ET; and Citi's Global Healthcare Conference on Thursday, December 5 at 9:30 a.m. ET The live webcasts of these events can be accessed from the investors section of BeiGene's website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. An archived replay will be available for 90 days following the event. About BeiGene BeiGene, which plans to ch
- SECSEC Form 144 filed by BeiGene Ltd.144 - BeiGene, Ltd. (0001651308) (Subject)
- PRLabcorp CFO Glenn Eisenberg Announces Plans to RetireJulia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.
- SECBeiGene Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BeiGene, Ltd. (0001651308) (Filer)
BGNE FAQ
7 questionsWhat does BeiGene Ltd. do?
BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China and the United States. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple...Where does BGNE stock trade?
BeiGene Ltd. (BGNE) is listed on NASDAQ.What sector and industry is BGNE in?
BeiGene Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did BeiGene Ltd. go public?
BeiGene Ltd. (BGNE) completed its IPO in 2016.What are analysts saying about BGNE?
BeiGene Ltd. has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Overweight on 2024-12-03.What companies are similar to BGNE?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BGNE side-by-side with any of them on Quantisnow.How can I track BGNE on Quantisnow?
Quantisnow aggregates BeiGene Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BGNE to receive live email and push alerts on every new disclosure.